[CHRS] Coherus BioSciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 28.05 Change: 0.05 (0.18%)
Ext. hours: Change: 0 (0%)

chart CHRS

Refresh chart

Strongest Trends Summary For CHRS

CHRS is in the medium-term up 88% in 2 years. In the long-term up 72% above S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -63.81% Sales Growth - Q/Q-10.52% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-50.75% ROE-203.75% ROI
Current Ratio2.77 Quick Ratio Long Term Debt/Equity Debt Ratio1.36
Gross Margin Operating Margin-245.92% Net Profit Margin-274.14% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-730 K Cash From Investing Activities-1.31 M Cash From Operating Activities-33.06 M Gross Profit
Net Profit-40.73 M Operating Profit-36.75 M Total Assets153.15 M Total Current Assets143.9 M
Total Current Liabilities51.91 M Total Debt Total Liabilities115 M Total Revenue5.81 M
Technical Data
High 52 week23.37 Low 52 week8.38 Last close19.15 Last change-2.84%
RSI61.92 Average true range1.22 Beta1.59 Volume340.72 K
Simple moving average 20 days6% Simple moving average 50 days-0.5% Simple moving average 200 days29.13%
Performance Data
Performance Week-4.35% Performance Month-3.04% Performance Quart9.62% Performance Half36.01%
Performance Year4.36% Performance Year-to-date111.6% Volatility daily4.49% Volatility weekly10.05%
Volatility monthly20.59% Volatility yearly71.32% Relative Volume232.26% Average Volume1.11 M
New High New Low

News

2020-05-26 18:16:00 | Essent Group Set to Join S&P MidCap 400; Coherus BioSciences, Patterson-UTI Energy to Join S&P SmallCap 600

2020-05-26 12:53:42 | Is Coherus BioSciences a Buy?

2020-05-21 12:47:42 | 3 Stocks Trading at Attractive Valuations

2020-05-13 19:08:15 | Coherus Is a ‘Top Pick’ for COVID-19 Environment, Says Top Analyst

2020-05-10 22:47:26 | Were Hedge Funds Right About Coherus Biosciences Inc CHRS?

2020-05-10 08:59:51 | Earnings Update: Coherus BioSciences, Inc. NASDAQ:CHRS Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

2020-05-08 19:33:38 | Edited Transcript of CHRS earnings conference call or presentation 7-May-20 8:30pm GMT

2020-05-08 17:30:32 | Coherus BioSciences Inc CHRS Q1 2020 Earnings Call Transcript

2020-05-08 13:05:43 | Those Who Purchased Coherus BioSciences NASDAQ:CHRS Shares Five Years Ago Have A 31% Loss To Show For It

2020-05-07 16:08:48 | Coherus BioSciences Reports First Quarter 2020 Financial Results

2020-05-04 09:30:10 | Coherus BioSciences Management to Present at BofA Securities 2020 Health Care Conference

2020-04-30 12:34:04 | Coherus BioSciences CHRS Earnings Expected to Grow: Should You Buy?

2020-04-22 09:30:10 | Coherus BioSciences to Report First Quarter Financial Results on May 7th

2020-04-21 17:39:00 | Coherus Biosciences Shows Rising Relative Price Performance; Still Working On Building Base

2020-04-16 07:27:11 | Check These 7 Top-Ranked Stocks With Solid Net Profit Margins

2020-04-15 00:05:36 | Coherus BioSciences Prices $200.0 Million Convertible Senior Subordinated Notes Offering

2020-04-14 07:52:38 | Coherus BioSciences Announces Proposed Convertible Senior Subordinated Notes Offering

2020-04-13 09:23:08 | Coherus BioSciences Provides First Quarter 2020 Financial Update and Fiscal Year 2020 COVID-19 Impact Insights

2020-04-08 10:49:02 | The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products

2020-04-07 06:59:10 | Signs of Coronavirus Slowdown Pep Up Wall Street: 5 Winners

2020-03-26 08:34:12 | Is Coherus BioSciences CHRS Stock a Solid Choice Right Now?

2020-03-20 09:30:10 | Coherus BioSciences Announces New Employment Inducement Grants

2020-03-13 18:53:40 | Edited Transcript of CHRS earnings conference call or presentation 27-Feb-20 9:30pm GMT

2020-03-09 05:01:09 | Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities

2020-03-05 16:09:45 | Coherus BioSciences Management to Present at Barclays Global Healthcare Conference 2020

2020-03-05 07:00:10 | United States Manufactured UDENYCA® pegfilgrastim-cbqv Well Positioned to Meet Market Demand

2020-02-29 08:54:58 | Coherus BioSciences, Inc. Just Missed EPS By 10%: Here's What Analysts Think Will Happen Next

2020-02-27 16:01:10 | Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results

2020-02-26 09:30:10 | Coherus BioSciences Management to Present at the 40th Annual Cowen Healthcare Conference

2020-02-24 09:43:02 | Coherus CHRS to Report Q4 Earnings: What's in the Cards?

2020-02-20 11:19:25 | Coherus BioSciences Announces New Employment Inducement Grants

2020-02-11 11:30:04 | Has Coherus BioSciences CHRS Outpaced Other Medical Stocks This Year?

2020-02-07 12:00:05 | Coherus BioSciences CHRS Upgraded to Strong Buy: Here's Why

2020-02-06 09:34:50 | Coherus BioSciences to Report Fourth Quarter and Full Year Financial Results on February 27th

2020-01-23 11:30:04 | Has Coherus BioSciences CHRS Outpaced Other Medical Stocks This Year?

2020-01-17 08:16:01 | Arena's ARNA Heart Failure Candidate Gets Fast Track Status

2020-01-13 08:30:10 | Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States

2020-01-08 08:53:01 | Amarin Posts '19 Preliminary Results, Gives 2020 Expense View

2020-01-07 11:30:04 | Is Coherus BioSciences CHRS Stock Outpacing Its Medical Peers This Year?

2020-01-07 09:59:02 | Protagonist PTGX Starts Study on PTG-300 for Blood Disorder

2020-01-03 09:55:02 | Pulmatrix Surges on License Agreement With Johnson & Johnson

2020-01-03 09:30:10 | Coherus BioSciences Management to Present at the 38th Annual J.P. Morgan Healthcare Conference

2020-01-03 09:01:02 | Arena ARNA Expands Strategic Deal With Beacon Discovery

2019-12-30 09:44:02 | Flexion's FLXN Stock Up on FDA Approval for Zilretta sNDA

2019-12-19 11:30:04 | Has Coherus BioSciences CHRS Outpaced Other Medical Stocks This Year?

2019-12-16 08:55:01 | 5 Biotech Stocks Set for Continued Rally in 2020

2019-12-07 12:25:53 | Is Coherus Biosciences Inc CHRS A Good Stock To Buy ?

2019-12-03 08:51:01 | Top Ranked Momentum Stocks to Buy for December 3rd

2019-11-26 11:27:04 | Top Ranked Momentum Stocks to Buy for November 26th

2019-11-19 09:36:02 | Alkermes to Acquire Rodin Therapeutics, Boost CNS Pipeline